The White House announced nine additional “most-favored nation”-style voluntary pricing deals with drugmakers, adding companies including Alcon, Astellas, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB to a growing list of signatories. The administration said the deals are intended to lower prices and help avoid tariffs tied to CMS pilot programs under review. The terms described by the administration mirror earlier agreements: sell new medications to U.S. patients at prices comparable to the lowest in peer countries, offer drugs to Medicaid programs at MFN prices, and in some cases support domestic manufacturing and U.S. medical stockpiles. For manufacturers, the announcements extend a fast-moving policy environment where commercial strategy is increasingly intertwined with federal pricing frameworks and tariff risk.